MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer
María Dolores Fenor, Sergio Ruiz‐Llorente, Juan Francisco Rodríguez-Moreno, Eduardo Caleiras, Juan Carlos Torrego Seijo, Elena Sevillano-Fernández, Paloma Navarro, Mónica Yagüe-Fernández, Sandra Amarilla‐Quintana, Arántzazu Barquín, Jesús García-Donás
Topics & Concepts
TrametinibMedicineProstate cancerMEK inhibitorCancerCancer researchDruggabilityFusion geneProstateOncologyDabrafenibInternal medicineMAPK/ERK pathwayKinaseGeneBiologyVemurafenibMetastatic melanomaCell biologyBiochemistryMelanoma and MAPK PathwaysProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment